### (19) World Intellectual Property Organization International Bureau



# 

## (43) International Publication Date 29 April 2004 (29.04.2004)

#### PCT

## (10) International Publication Number WO 2004/034985 A2

(51) International Patent Classification7:

**A61K** 

[JP/JP]; 23-18 Minamiyama-cyo, Syowa-ku, Nagoya-shi, Aichi 466-0835 (JP).

(21) International Application Number:

PCT/US2003/032625

(22) International Filing Date: 15 October 2003 (15.10.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/418,915

16 October 2002 (16.10.2002)

- (71) Applicant (for all designated States except US): CORPORATION SMITHKLINE **BEECHAM** [US/US]; One Franklin Plaza, Philadelphia, PA 19101 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): BURGESS, Joelle, L. [US/US]; c/o GlaxoSmithKline, 709 Swedeland Road, King of Prussia, PA 19406 (US). CALLAHAN, John, F. [US/US]; c/o GlaxoSmithKline, 709 Swedeland Road, King of Prussia, PA 19406 (US). HAMAJIMA, Toshihiro [JP/JP]; c/o GlaxoSmithKline KK, 43 Wadai, Tsukuba-shi, Ibaraki 300-4247 (JP). IDA, Satoru [JP/NE]; c/o Glaxo-SmithKline KK, 43 Wadai, Tsukuba-shi, Ibaraki 300-4247 (JP). TANG, Jun [CN/JP]; c/o GlaxoSmithKline KK, 43 Wadai, Tsukuba-shi, Ibaraki 300-4247 (JP). MORI, Ichiro

- (74) Agents: LEVY, David, J. et al.; GlaxoSmithKline, Corporate Intellectual Property Department, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

#### Published:

without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: CHEMICAL COMPOUNDS

(57) Abstract: 3-carboxy quinoline derivatives, which are useful as YAK3 inhibitors are described herein. The described invention also includes methods of making such 3-carboxy quinoline derivatives as well as methods of using the same in the treatment of diseases mediated by inappropriate YAK3 activity.

## (19) World Intellectual Property **Organization** International Bureau



# 

(43) International Publication Date 29 April 2004 (29.04.2004)

**PCT** 

## (10) International Publication Number WO 2004/034985 A3

- (51) International Patent Classification<sup>7</sup>: A61K 31/47
- C07D 453/02.
- (21) International Application Number:

PCT/US2003/032625

- (22) International Filing Date: 15 October 2003 (15.10.2003)
- (25) Filing Language:

English

(26) Publication Language:

**English** 

- (30) Priority Data: 60/418,915 16 October 2002 (16.10.2002) US
- (71) Applicant (for all designated States except US): **SMITHKLINE BEECHAM** CORPORATION [US/US]; One Franklin Plaza, Philadelphia, PA 19101 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): BURGESS, Joelle, L. [US/US]; c/o GlaxoSmithKline, 709 Swedeland Road, King of Prussia, PA 19406 (US). CALLAHAN, John, F. [US/US]; c/o GlaxoSmithKline, 709 Swedeland Road, King of Prussia, PA 19406 (US). HAMAJIMA, Toshihiro [JP/JP]; c/o GlaxoSmithKline KK, 43 Wadai, Tsukuba-shi, Ibaraki 300-4247 (JP). IDA, Satoru [JP/NE]; c/o Glaxo-SmithKline KK, 43 Wadai, Tsukuba-shi, Ibaraki 300-4247 (JP). TANG, Jun [CN/JP]; c/o GlaxoSmithKline KK, 43 Wadai, Tsukuba-shi, Ibaraki 300-4247 (JP). MORI, Ichiro [JP/JP]; 23-18 Minamiyama-cyo, Syowa-ku, Nagoya-shi, Aichi 466-0835 (JP).

- (74) Agents: LEVY, David, J. et al.; GlaxoSmithKline, Corporate Intellectual Property Department, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

#### Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- (88) Date of publication of the international search report: 10 September 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: CHEMICAL COMPOUNDS

(57) Abstract: 3-carboxy quinoline derivatives, which are useful as YAK3 inhibitors are described herein. The described invention also includes methods of making such 3-carboxy quinoline derivatives as well as methods of using the same in the treatment of diseases mediated by inappropriate YAK3 activity.

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/32625

According to International Patent Classification (IPC) or to both national classification and IPC  B. FIELDS SEARCHED  Minimum documentation searched (classification system followed by classification symbols)  U.S.: 546/134; 514/313  Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched  Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  EAST; STN CAS ON LINE  C. DOCUMENTS CONSIDERED TO BE RELEVANT  Category * Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No.  A US 5,441,949 A (JUNG et al.) 15 August 1995 (15.08.1995) entire document  1-7
Minimum documentation searched (classification system followed by classification symbols) U.S.: 546/134; 514/313  Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched  Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) EAST; STN CAS ON LINE  C. DOCUMENTS CONSIDERED TO BE RELEVANT  Category * Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No.
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) EAST; STN CAS ON LINE  C. DOCUMENTS CONSIDERED TO BE RELEVANT Category * Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No.
C. DOCUMENTS CONSIDERED TO BE RELEVANT  Category * Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No.
Category * Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No.
Category Clauded of document, while and the specific of the sp
A US 5,441,949 A (JUNG et al.) 15 August 1995 (15.08.1995) entire document 1-7
Further documents are listed in the continuation of Box C. See patent family annex.
* Special categories of cited documents:  "T"  later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention  "A" document defining the general state of the art which is not considered to be of particular relevance
"X"  document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)  "O" document referring to an oral disclosure, use, exhibition or other means  "O" document referring to an oral disclosure, use, exhibition or other means  "O" document referring to an oral disclosure, use, exhibition or other means
"P" document published prior to the international filing date but later than the "&" document member of the same patent family priority date claimed
Date of the actual completion of the international search  Date of mailing of the international search report
11 July 2004 (11.07.2004) 03 AUG 2004
Name and mailing address of the ISA/US  Authorized officer
Mail Stop PCT, Atm: ISA/US Commissioner for Patents  Kamal Saeed, Ph.D.
P.O. Box 1450 Alexandria, Virginia 22313-1450 Telephone No. (571) 272-1600
Facsimile No. (703)305-3230  Form PCT/ISA/210 (second sheet) (July 1998)